Zoetis Inc. (NYSE:ZTS) Shares Purchased by Nicholas Hoffman & Company LLC.

Nicholas Hoffman & Company LLC. boosted its position in Zoetis Inc. (NYSE:ZTS) by 21.3% during the 2nd quarter, Holdings Channel reports. The fund owned 2,014 shares of the company’s stock after acquiring an additional 354 shares during the quarter. Nicholas Hoffman & Company LLC.’s holdings in Zoetis were worth $375,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of ZTS. AAFMAA Wealth Management & Trust LLC raised its holdings in Zoetis by 0.3% during the second quarter. AAFMAA Wealth Management & Trust LLC now owns 19,390 shares of the company’s stock worth $3,614,000 after purchasing an additional 50 shares in the last quarter. Chicago Partners Investment Group LLC grew its position in Zoetis by 3.1% in the 2nd quarter. Chicago Partners Investment Group LLC now owns 1,650 shares of the company’s stock valued at $331,000 after buying an additional 50 shares during the last quarter. 1ST Source Bank grew its position in Zoetis by 0.7% in the 2nd quarter. 1ST Source Bank now owns 7,003 shares of the company’s stock valued at $1,305,000 after buying an additional 50 shares during the last quarter. Highland Private Wealth Management grew its position in Zoetis by 3.3% in the 2nd quarter. Highland Private Wealth Management now owns 1,622 shares of the company’s stock valued at $303,000 after buying an additional 52 shares during the last quarter. Finally, Founders Financial Alliance LLC grew its position in Zoetis by 4.1% in the 2nd quarter. Founders Financial Alliance LLC now owns 1,501 shares of the company’s stock valued at $281,000 after buying an additional 59 shares during the last quarter. 89.53% of the stock is currently owned by hedge funds and other institutional investors.

In other news, CEO Kristin C. Peck sold 14,500 shares of the firm’s stock in a transaction on Wednesday, August 25th. The shares were sold at an average price of $203.55, for a total value of $2,951,475.00. Following the transaction, the chief executive officer now owns 43,424 shares of the company’s stock, valued at approximately $8,838,955.20. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Roxanne Lagano sold 22,450 shares of the firm’s stock in a transaction on Thursday, July 22nd. The shares were sold at an average price of $199.18, for a total transaction of $4,471,591.00. The disclosure for this sale can be found here. Insiders sold a total of 48,003 shares of company stock valued at $9,711,854 in the last three months. 0.17% of the stock is currently owned by corporate insiders.

NYSE:ZTS opened at $203.55 on Wednesday. The company has a market capitalization of $96.47 billion, a PE ratio of 51.02, a price-to-earnings-growth ratio of 3.31 and a beta of 0.64. The company has a quick ratio of 2.51, a current ratio of 3.37 and a debt-to-equity ratio of 1.51. Zoetis Inc. has a 52-week low of $141.41 and a 52-week high of $210.10. The stock has a fifty day simple moving average of $203.07 and a 200-day simple moving average of $181.17.

Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, August 5th. The company reported $1.19 earnings per share for the quarter, beating the consensus estimate of $1.08 by $0.11. Zoetis had a net margin of 25.76% and a return on equity of 53.87%. During the same period in the prior year, the business posted $0.89 earnings per share. As a group, equities analysts anticipate that Zoetis Inc. will post 4.53 earnings per share for the current year.

Several equities research analysts have commented on the stock. Argus boosted their target price on shares of Zoetis from $195.00 to $225.00 and gave the stock a “buy” rating in a research report on Wednesday, August 25th. Cantor Fitzgerald boosted their target price on shares of Zoetis from $210.00 to $238.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 13th. Credit Suisse Group boosted their target price on shares of Zoetis from $206.00 to $230.00 and gave the stock an “outperform” rating in a research report on Monday, August 9th. Zacks Investment Research upgraded shares of Zoetis from a “hold” rating to a “buy” rating and set a $186.00 target price on the stock in a research report on Tuesday, June 1st. Finally, Raymond James lowered shares of Zoetis from an “outperform” rating to a “market perform” rating in a research report on Friday, July 16th. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $199.08.

Zoetis Company Profile

Zoetis, Inc discovers, develops, and manufactures a portfolio of animal health medicines and vaccines. The firm operates through the following segments: United States &International. Its products are complemented by diagnostic products, genetic tests, bio devices, and services. These are designed to meet the needs of veterinarians and the livestock farmers and companion animal.

Featured Article: What is the accumulation/distribution indicator?

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.